The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 28, 2025

Filed:

Feb. 13, 2019
Applicant:

Ligand Pharmaceuticals Incorporated, San Diego, CA (US);

Inventors:

Lin Zhi, Austin, TX (US);

Ian Henderson, Plainsboro, NJ (US);

Joseph Kaloko, Durham, NC (US);

Martin Osterhout, Raleigh, NC (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/185 (2006.01); A61K 31/155 (2006.01); A61K 31/366 (2006.01); A61K 31/427 (2006.01); A61K 31/4439 (2006.01); A61K 31/455 (2006.01); A61K 31/64 (2006.01); A61K 31/702 (2006.01); A61K 31/7032 (2006.01); A61K 38/28 (2006.01); A61K 38/31 (2006.01); A61K 45/06 (2006.01); C07C 67/00 (2006.01); C07C 67/343 (2006.01); C07C 201/12 (2006.01); C07C 209/36 (2006.01); C07C 231/02 (2006.01); C07C 231/12 (2006.01); C07C 309/24 (2006.01); C07C 315/04 (2006.01); C07C 315/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/185 (2013.01); A61K 31/155 (2013.01); A61K 31/366 (2013.01); A61K 31/427 (2013.01); A61K 31/4439 (2013.01); A61K 31/455 (2013.01); A61K 31/64 (2013.01); A61K 31/702 (2013.01); A61K 31/7032 (2013.01); A61K 38/28 (2013.01); A61K 38/31 (2013.01); A61K 45/06 (2013.01); C07C 67/00 (2013.01); C07C 67/343 (2013.01); C07C 201/12 (2013.01); C07C 209/36 (2013.01); C07C 231/02 (2013.01); C07C 231/12 (2013.01); C07C 309/24 (2013.01); C07C 315/04 (2013.01); C07C 315/06 (2013.01); C07B 2200/13 (2013.01);
Abstract

Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.


Find Patent Forward Citations

Loading…